Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Etoposide 31Carboplatin 30atezolizumab 17durvalumab 16Cisplatin 14Topotecan 11PM 01183 11Specimen Handling 9pembrolizumab 8Magnetic Resonance Spectroscopy 7olaparib 5Radiotherapy 5berzosertib 4anlotinib 4Paclitaxel 4Nivolumab 4Irinotecan 4Drug Therapy 4tremelimumab 3toripalimab 3tislelizumab 3Temozolomide 3Radiosurgery 3Injections 3Docetaxel 3Biopsy 3Bevacizumab 3AMG 757 3sacituzumab govitecan 2monalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × fluoromisonidazole × 90 days × Clear all
NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
122 enrolled 16 charts
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡